UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

JID innovations, 2022-09, Vol.2 (5), p.100131-100131, Article 100131

2022

Volltextzugriff (PDF)

The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study

The Journal of pediatrics, 2022-07, Vol.246, p.220-226.e5

2022

Volltextzugriff (PDF)

Nomenclature and clinical phenotypes of atopic dermatitis

Therapeutic advances in chronic disease, 2021, Vol.12, p.20406223211002979-20406223211002979

2021

Volltextzugriff (PDF)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Acta dermato-venereologica, 2021-11, Vol.101 (11), p.adv00585-adv00585

2021

Volltextzugriff (PDF)

Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

Dermatology and therapy, 2024-03, Vol.14 (3), p.819-821

2024

Volltextzugriff (PDF)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Acta dermato-venereologica, 2021-07, Vol.101 (7), p.adv00504-adv00504

2021

Volltextzugriff (PDF)

Atopic dermatitis in the pediatric population

Annals of allergy, asthma, & immunology, 2021-04, Vol.126 (4), p.417-428.e2

2021

Volltextzugriff (PDF)

Sub-optimal Application of a High SPF Sunscreen Prevents Epidermal DNA Damage in Vivo

Acta dermato-venereologica, 2018-10, Vol.98 (9), p.880-887

2018

Volltextzugriff (PDF)

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan

Journal of clinical medicine, 2023-04, Vol.12 (8), p.2988

2023

Volltextzugriff (PDF)

Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study

Annals of allergy, asthma, & immunology, 2021-04, Vol.126 (4), p.417-428.e2

2021

Volltextzugriff (PDF)

Efficacy of dupilumab in moderate and severe atopic dermatitis

JEADV clinical practice, 2023-06, Vol.2 (2), p.247-260

2023

Volltextzugriff (PDF)

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1328-1336

2020

Volltextzugriff (PDF)

Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis

Allergy (Copenhagen), 2022-11, Vol.77 (11), p.3388-3397

2022

Volltextzugriff (PDF)

Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial

Journal of the American Academy of Dermatology, 2021-02, Vol.84 (2), p.495-497

2021

Volltextzugriff (PDF)

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

American journal of clinical dermatology, 2020-02, Vol.21 (1), p.119-131

2020

Volltextzugriff (PDF)

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis

British journal of dermatology (1951), 2023-07, Vol.189 (2), p.238-240

2023

Volltextzugriff (PDF)

The disease burden of pediatric patients with atopic dermatitis in Japan

Pediatric dermatology, 2023-09, Vol.40 (5), p.851-856

2023

Volltextzugriff (PDF)

Burden of atopic dermatitis in paediatric patients: an international cross-sectional study

British journal of dermatology (1951), 2024-05, Vol.190 (6), p.846-857

2024

Volltextzugriff (PDF)

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials

JAMA dermatology (Chicago, Ill.), 2023-03, Vol.159 (3), p.255

2023

Volltextzugriff (PDF)

Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial

American journal of clinical dermatology, 2023-09, Vol.24 (5), p.787-798

2023

Volltextzugriff (PDF)

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Drug design, development and therapy, 2024-01, Vol.18, p.277-289

2024

Volltextzugriff (PDF)

Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-06, Vol.10 (6), p.1515-1526

2022

Volltextzugriff (PDF)

Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-03, Vol.9 (3), p.1212-1223.e6

2021

Volltextzugriff (PDF)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Dermatologic therapy, 2021-08, Vol.11 (4), p.1357-1372

2021

Volltextzugriff (PDF)

Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24

Italian Journal of Dermatology and Venereology, 2022-02, Vol.157 (1), p.39

2022

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(78)
Buchkapitel
(1)

Sprache

Englisch
(77)
Portugiesisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study

Nomenclature and clinical phenotypes of atopic dermatitis

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Atopic dermatitis in the pediatric population

Sub-optimal Application of a High SPF Sunscreen Prevents Epidermal DNA Damage in Vivo

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan

Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study

Efficacy of dupilumab in moderate and severe atopic dermatitis

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS

Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis

Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis

The disease burden of pediatric patients with atopic dermatitis in Japan

Burden of atopic dermatitis in paediatric patients: an international cross-sectional study

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials

Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24

Suchergebnisse filtern